189 related articles for article (PubMed ID: 26194802)
1. Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation.
Long M; Wu J; Hao J; Liu W; Tang Y; Li X; Su H; Qiu W
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1077-84. PubMed ID: 26194802
[TBL] [Abstract][Full Text] [Related]
2. Selenocystine inhibits JEG-3 cell growth
Zhao M; Hou Y; Fu X; Li D; Sun J; Fu X; Wei Z
J Cancer Res Ther; 2018; 14(7):1540-1548. PubMed ID: 30589036
[TBL] [Abstract][Full Text] [Related]
3. Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation.
Chen T; Wong YS
J Agric Food Chem; 2008 Nov; 56(22):10574-81. PubMed ID: 18959417
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53.
Sutton KM; Greenshields AL; Hoskin DW
Nutr Cancer; 2014; 66(3):408-18. PubMed ID: 24579801
[TBL] [Abstract][Full Text] [Related]
6. Selenocystine induces reactive oxygen species-mediated apoptosis in human cancer cells.
Chen T; Wong YS
Biomed Pharmacother; 2009 Feb; 63(2):105-13. PubMed ID: 18511231
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
8. Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
Zhang QQ; Chen J; Zhou DL; Duan YF; Qi CL; Li JC; He XD; Zhang M; Yang YX; Wang L
Int J Biol Sci; 2017; 13(4):471-479. PubMed ID: 28529455
[TBL] [Abstract][Full Text] [Related]
9. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
10. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
Fang Y; Zhang Q; Wang X; Yang X; Wang X; Huang Z; Jiao Y; Wang J
Int J Oncol; 2016 Mar; 48(3):1016-28. PubMed ID: 26783066
[TBL] [Abstract][Full Text] [Related]
11. F1012-2 inhibits the growth of triple negative breast cancer through induction of cell cycle arrest, apoptosis, and autophagy.
Tian S; Chen Y; Yang B; Lou C; Zhu R; Zhao Y; Zhao H
Phytother Res; 2018 May; 32(5):908-922. PubMed ID: 29468753
[TBL] [Abstract][Full Text] [Related]
12. Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis.
Song X; Wu JQ; Yu XF; Yang XS; Yang Y
Neoplasma; 2018 Nov; 65(6):898-906. PubMed ID: 30334455
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
14. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells.
Eldehna WM; El-Naggar DH; Hamed AR; Ibrahim HS; Ghabbour HA; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):309-318. PubMed ID: 29281924
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
16. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
17. Selenocystine potentiates cancer cell apoptosis induced by 5-fluorouracil by triggering reactive oxygen species-mediated DNA damage and inactivation of the ERK pathway.
Fan C; Chen J; Wang Y; Wong YS; Zhang Y; Zheng W; Cao W; Chen T
Free Radic Biol Med; 2013 Dec; 65():305-316. PubMed ID: 23837948
[TBL] [Abstract][Full Text] [Related]
18. Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo.
Zhao T; Sun Q; del Rincon SV; Lovato A; Marques M; Witcher M
PLoS One; 2014; 9(3):e92853. PubMed ID: 24658335
[TBL] [Abstract][Full Text] [Related]
19. Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
Chen L; Long C; Nguyen J; Kumar D; Lee J
Bioorg Med Chem Lett; 2018 Feb; 28(3):420-424. PubMed ID: 29287960
[TBL] [Abstract][Full Text] [Related]
20. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]